摘要
目的:胸腺肽β10(thymosinβ10,TMSβ10)在部分恶性肿瘤中呈过表达状态,但其在口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)中的表达尚无报道。本研究旨在探讨TMSβ10在OSCC组织中的表达和潜在的作用机制。方法:收集OSCC样本基因芯片和RNA测序表达矩阵,提取TMSβ10 mRNA表达值;采用标准化均值差(standardized mean difference,SMD)总受试者工作特征(summary receiver operating characteristic,SROC)曲线评估TMSβ10表达的临床价值,并进行TMSβ10相关基因的功能富集分析,再以免疫组织化学实验进行验证。结果:与252份非癌口腔组织相比,TMSβ10在677例OSCC组织中显著升高[SMD=1.68(0.95~2.42)],且对于OSCC具有高区分能力[SROC曲线下面积(area under the curve,AUC)=0.95,95%CI为0.92~0.96]。TMSβ10相关基因生物学功能主要富集于伤口愈合、蛋白酶体蛋白等方面。此外,多个数据集的分析显示纤维连接蛋白1(fibronectin 1,FN1)与TMSβ10基因之间存在显著的正相关性(r为0.34~0.83,均P<0.05),被鉴定为TMSβ10伤口愈合通路中的枢纽基因。结论:TMSβ10表达上调可能具有促进OSCC发生的作用。
Objective:Thymosinβ10(TMSβ10)has been found to be overexpressed in some malignant tumors,but its value in oral squamous cell carcinoma(OSCC)has not yet been reported.This study aims to investigate the significance of TMSβ10 expression in OSCC tissues and its potential mechanisms.Methods:Gene chip and RNA sequencing data from OSCC samples were collected.The mRNA expression levels of TMSβ10 were extracted,and standardized mean difference(SMD)was calculated.A summary receiver operating characteristic(SROC)curve was drawn to evaluate the clinical value of TMSβ10 expression.Additionally,functional enrichment analysis of TMSβ10-related genes and immunohistochemical validation were conducted.Results:Compared to 252 non-cancerous oral tissues,TMSβ10 expression was significantly elevated in 677 OSCC tissues[SMD=1.68(0.95-2.42)],showing a high discrimination ability for OSCC[area under the curve(AUC)=0.95,95%CI 0.92-0.96].The biological functions of TMSβ10-related genes were mainly enriched in pathways related to wound healing and proteasome proteins.Furthermore,analysis of multiple datasets revealed a significant positive correlation between fibronectin 1(FN1)and TMSβ10 genes(r were 0.34-0.83,all P<0.05),identifying as a key gene in the wound healing pathway involving TMSβ10.Conclusion:The up-regulation of TMSβ10 expression may promote the development of OSCC.
作者
陈昶
黄颖欣
毛荣军
李建棣
吴桐
莫超华
CHEN Chang;HUANG Yingxin;MAO Rongjun;LI Jiandi;WU Tong;MO Chaohua(Department of Pathology,Wuzhou Red Cross Hospital,Wuzhou Guangxi 543000;Department of Pathology,Foshan Hospital of Traditional Chinese Medicine,Foshan Guangdong 528000;Department of Pathology,First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)
出处
《临床与病理杂志》
CAS
2024年第7期951-963,共13页
Journal of Clinical and Pathological Research
基金
佛山市自筹经费类科技创新项目(2220001005580)
佛山市“十四五”医学重点专科项目(FSZD145010)。
